HepG2-based Cytotoxicity Safety Screening Service
Why Use HepG2 Cell Line for Cytotoxicity Testing?
The HepG2 cell line, derived from human hepatocellular carcinoma, is widely utilized in cytotoxicity testing due to its close resemblance to primary human hepatocytes in terms of metabolic activity and enzyme expression. These cells exhibit a high level of differentiation and maintain various essential liver-specific functions, including enzyme induction, bile acid synthesis, and the secretion of plasma proteins. This makes HepG2 an advantageous in vitro model for evaluating the hepatotoxicity of chemical compounds, drugs, and environmental toxins. HepG2 cells' robust and reproducible nature facilitates high-throughput screening and accurate prediction of the hepatotoxicity potential, aiding in the early stages of drug development.
HepG2 vs H4-II-E-C3 Cell Lines
When compared to the H4-II-E-C3 cell line, which is derived from rat hepatoma, HepG2 offers a more relevant human-specific context that can provide more clinically translatable insights into human liver responses. This human-origin enhances the overall predictive power and applicability of cytotoxicity results, thereby making HepG2 an indispensable tool in toxicological research and pharmaceutical testing.
HepG2-based Cytotoxicity Screening Services
At Creative Biolabs, we offer state-of-the-art HepG2-based cytotoxicity screening services designed to help researchers comprehensively assess the cytotoxicity profile of various compounds. Our services utilize advanced cell viability assays to determine how compounds affect HepG2 cell health and viability, indicating potential cytotoxic or cytostatic effects.
Our cytotoxicity screening services use HepG2 cells as our primary model, leveraging their human liver relevance to predict in vivo metabolic interactions accurately. Our experienced team of scientists meticulously handles and cultures HepG2 cells under optimal conditions to ensure reliable and reproducible results. By applying our rigorous cell viability assays, we provide researchers with critical safety insights, guiding the development of safer and more effective compounds.
Cell Viability Assay: Measuring Cytotoxicity in HepG2 Cells
Our cytotoxicity screening service is founded on the cell viability assay, a highly robust and sensitive method for assessing a compound's impact on cell health. This assay is used for the quantification of ATP content in HepG2 cells, which we measure using a luminescent detection system. The process begins with the exposure of HepG2 cells to varying concentrations of the test compounds. After an appropriate incubation period, we evaluate cell viability by quantifying intracellular ATP levels, a reliable marker of metabolically active cells. Our luminescent detection system employs a luciferase enzyme that catalyzes a reaction with ATP, resulting in the emission of a luminescent signal. The intensity of this signal corresponds directly to the ATP concentration, thereby providing an accurate and quantitative measure of cell viability.
Published Data
To evaluate the cytotoxicity levels of Lycopene, HepG2 cells treated with various concentrations of Lycopene were subjected to a cell viability assay. The results indicated that Lycopene did not significantly affect cellular viability at concentrations up to 30 µM.
Fig.1 Cytotoxicity assay of the HepG2 cells after treatment with Lycopene at different concentrations.1,2
References
-
Reshmitha, T. R., and P. Nisha. "Lycopene mitigates acrylamide and glycidamide induced cellular toxicity via oxidative stress modulation in HepG2 cells." Journal of Functional Foods 80 (2021): 104390.
-
Distributed under Open Access license CC BY 4.0, without.
For Research Use Only | Not For Clinical Use
Download our brochure